EP1011709A1 - Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine - Google Patents

Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine

Info

Publication number
EP1011709A1
EP1011709A1 EP98951917A EP98951917A EP1011709A1 EP 1011709 A1 EP1011709 A1 EP 1011709A1 EP 98951917 A EP98951917 A EP 98951917A EP 98951917 A EP98951917 A EP 98951917A EP 1011709 A1 EP1011709 A1 EP 1011709A1
Authority
EP
European Patent Office
Prior art keywords
seq
prosaposin
apoptosis
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98951917A
Other languages
German (de)
English (en)
Other versions
EP1011709A4 (fr
Inventor
John S. O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1011709A1 publication Critical patent/EP1011709A1/fr
Publication of EP1011709A4 publication Critical patent/EP1011709A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne un procédé permettant d'inhiber l'apoptose liée à la caspase, par l'administration d'agonistes du récepteur de la prosaposine. L'apoptose constitue un facteur causal majeur dans des maladies telles que la polyarthrite rhumatoïde, le syndrome du côlon irritable, l'insuffisance cardiaque globale, la sclérose en plaques, la maladie d'Alzheimer, la maladie de Parkinson, l'infarctus du myocarde et l'ischémie coronarienne.
EP98951917A 1997-09-09 1998-09-09 Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine Withdrawn EP1011709A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5835297P 1997-09-09 1997-09-09
US8812998P 1998-06-04 1998-06-04
US88129P 1998-06-04
PCT/US1998/019216 WO1999012559A1 (fr) 1997-09-09 1998-09-09 Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine
US58352P 2008-06-03

Publications (2)

Publication Number Publication Date
EP1011709A1 true EP1011709A1 (fr) 2000-06-28
EP1011709A4 EP1011709A4 (fr) 2003-06-18

Family

ID=26737533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98951917A Withdrawn EP1011709A4 (fr) 1997-09-09 1998-09-09 Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine

Country Status (5)

Country Link
EP (1) EP1011709A4 (fr)
JP (1) JP2001515866A (fr)
AU (1) AU9774698A (fr)
CA (1) CA2304108A1 (fr)
WO (1) WO1999012559A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
WO1999064062A1 (fr) * 1998-06-08 1999-12-16 Pharmacia & Upjohn Ab Nouvelle utilisation therapeutique d'amplificateurs de l'activite de la proteine kinase b (picb)
EP1097165A4 (fr) * 1998-07-13 2001-09-12 Parkash S Gill Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale
HUP0103994A3 (en) * 1998-09-09 2004-03-01 Myelos Corp San Diego Method of stimulating prosaposin receptor activity
AU772731B2 (en) * 1998-10-02 2004-05-06 Caritas St. Elizabeth's Medical Center Of Boston, Inc. AKT compositions for enhancing survival of cells
US7368420B1 (en) 1998-10-02 2008-05-06 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Akt compositions for enhancing survival of cells
ES2232434T3 (es) 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
JP2001010972A (ja) * 1999-06-30 2001-01-16 Masahiro Sakanaka プロサポシン関連ペプチドからなる細胞保護剤
WO2001055198A2 (fr) * 2000-01-26 2001-08-02 Memorec Medical Molecular Research Cologne Stoffel Gmbh Activateur de sphingolipide specifique de la peau et de l'estomac
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
DE10037759A1 (de) * 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
WO2005037304A1 (fr) * 2003-10-17 2005-04-28 Crucell Holland B.V. Traitement et prevention d'escarres de decubitus
US20050180974A1 (en) * 2003-10-24 2005-08-18 Medtronic, Inc. Extracellular TNF inhibitors for treating CNS disorders
EP3127549B1 (fr) * 2007-06-22 2019-12-18 Children's Medical Center Corporation Procédés et utilisations d'un fragment de saposine a
CA2943802A1 (fr) 2014-03-26 2015-10-01 Children's Medical Center Corporation Peptides de prosaposine cycliques et utilisations de ceux-ci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAMPANA W M ET AL: "Prosaptide, a peptide derived from prosaposin, induces motor endplate sprouting and prevents taxol neuropathy." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 21, no. 1-3, 1995, page 554 XP009008629 25th Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 11-16, 1995 ISSN: 0190-5295 *
HIRAIWA ET AL: "CELL DEATH PREVENTION, MITOGEN-ACTIVATED PROTEIN KINASE STIMULATION, AND INCREASED SULFATIDE CONCENTRATIONS IN SCHWANN CELLS AND OLIGODENDROCYTES BY PROSAPOSIN AND PROSAPTIDES" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, April 1997 (1997-04), pages 4778-4781, XP002135051 ISSN: 0027-8424 *
HOZUMI I ET AL: "Amelioration of spatial learning impairment and neuronal loss in rats with stab wounds by prosaposin." JOURNAL OF NEUROCHEMISTRY, vol. 69, no. SUPPL., 1997, page S249 XP009008631 Joint Sixteenth Biennial Meeting of the International Society for Neurochemistry and Twenty-eighth Annual Meeting of the American Society for Neurochemistry;Boston, Massachusetts, USA; July 20-26, 1997 ISSN: 0022-3042 *
OTERO DEBORAH A C ET AL: "Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model by Prosaptide(R) TX14(A)." NEUROSCIENCE LETTERS, vol. 270, no. 1, 23 July 1999 (1999-07-23), pages 29-32, XP002238179 ISSN: 0304-3940 *
See also references of WO9912559A1 *
TAYLOR E M ET AL: "Prosaposin and prosaptide prevent TNF-alpha-induced cell death in NS20Y and CG4 cells." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, page 2226 XP009008626 27th Annual Meeting of the Society for Neuroscience;New Orleans, Louisiana, USA; October 25-30, 1997 ISSN: 0190-5295 *
TSUBOI K ET AL: "Prosaposin and prosaptide can prevent programmed cell death of rat cerebellar granule neurons." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, page 1439 XP009008627 27th Annual Meeting of the Society for Neuroscience;New Orleans, Louisiana, USA; October 25-30, 1997 ISSN: 0190-5295 *
TSUBOI K ET AL: "PROSAPOSIN PREVENTS PROGRAMMED CELL DEATH OF RAT CEREBELLAR GRANULENEURONS IN CULTURE" DEVELOPMENTAL BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 110, no. 2, 1998, pages 249-255, XP000915816 ISSN: 0165-3806 *
WAGNER ROCHELLE ET AL: "Prosaptide prevents hyperalgesia and reduces peripheral TNFR1 expression following TNF-alpha nerve injection." NEUROREPORT, vol. 9, no. 12, 24 August 1998 (1998-08-24), pages 2827-2831, XP009008642 ISSN: 0959-4965 *
YAN L ET AL: "A 14-mer prosaptide activates a G-protein receptor and diminishes calcium flux in synaptosomes." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, page 805 XP009009360 28th Annual Meeting of the Society for Neuroscience, Part 1;Los Angeles, California, USA; November 7-12, 1998 ISSN: 0190-5295 *
YAN LIZHEN ET AL: "ProsaptideTM D5 reverses hyperalgesia: Inhibition of calcium channels through a pertussis toxin-sensitive G-protein mechanism in the rat." NEUROSCIENCE LETTERS, vol. 278, no. 1-2, 7 January 2000 (2000-01-07), pages 120-122, XP002238180 ISSN: 0304-3940 *

Also Published As

Publication number Publication date
CA2304108A1 (fr) 1999-03-18
AU9774698A (en) 1999-03-29
EP1011709A4 (fr) 2003-06-18
JP2001515866A (ja) 2001-09-25
WO1999012559A1 (fr) 1999-03-18

Similar Documents

Publication Publication Date Title
EP1011709A1 (fr) Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine
EP0890105B1 (fr) Méthods pour le diagnostique, pour la production des médicaments et pour le criblage de substances relatives à la maladie d'Alzheimer et des peptides derivés de l'amyloid beta
JP4070803B2 (ja) 治療剤としてのプロサポシンおよびサイトカイン由来ペプチド
US5696080A (en) Pharmaceutical compositions comprising neurotrophic peptides derived from prosaposin
US7157422B2 (en) Glycogen synthase kinase-3 inhibitors
US6686334B2 (en) Use of inhibitors of protein kinase C epsilon to treat pain
JP2012176978A (ja) プロテインキナーゼｃのペプチドインヒビター
SK122898A3 (en) Methods of alleviating neuropathic pain using prosaposin-derived peptides
US20070066526A1 (en) Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
US20050164948A1 (en) Methods of treatment with prosaposin-derived peptides
KR20060114030A (ko) Ｆｐｒ 계열 수용체 매개 신호전달에 대하여 길항작용 하는펩티드
US20140213526A1 (en) Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
US8673852B2 (en) Methods of treating neuronal disorders using MNTF peptides and analogs thereof
CA2206321A1 (fr) Inhibition de la proliferation de cellules gliales
EP1093379B1 (fr) Utilisation d'inhibiteurs de la proteine kinase c epsilon dans le traitement de la douleur
US6207393B1 (en) Inhibition of intracellular signal transduction by 14-3-3-binding peptides
JP2008508363A (ja) δプロテインキナーゼＣの調節のためのペプチド配列
HUE024953T2 (en) Peptide inhibitors to mediate stress responses
EP0979238A1 (fr) Procedes pour soulager les douleurs neuropathiques
JP4094814B2 (ja) 血管新生抑制剤
US8106019B2 (en) CHEC-7 a novel sPLA2 inhibitor
US20020132759A1 (en) Remedies for diseases caused by insulin resistance
US20050009753A1 (en) Tri-peptides for neurological and neurobehavioral applications
WO2000047218A1 (fr) Regulation de la degenerescence des photorecepteurs
AU2002300005B2 (en) Method of alleviating neuropathic pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030506

17Q First examination report despatched

Effective date: 20031118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040330